Stocktoria
Anbio Biotechnology NNNN
Anbio Biotechnology financials (annual)
Bars are annual figures from 2023 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $8.6M | $8.2M | $6.7M |
| Gross profit | $7.5M | $5.9M | $3.4M |
| R&D expense | $201,305 | $454,227 | $134,700 |
| SG&A expense | $1.6M | $3.4M | $1.3M |
| Operating income | $5.8M | $2.0M | $2.0M |
| Income tax | $0 | $0 | $0 |
| Net income | $6.4M | $2.4M | $2.3M |
| EPS (diluted) | $0.15 | $0.06 | $0.10 |
| Operating cash flow | -$6.7M | $2.1M | $898,367 |
| Cash & equivalents | $7.8M | $11.8M | $9.7M |
| Total assets | $30.2M | $18.9M | $15.8M |
| Total liabilities | $87,836 | $1.7M | $993,060 |
| Shareholders' equity | $30.2M | $17.2M | $14.8M |
Growth · year-over-year · Revenue CAGR 13.5%
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue growth | +5.6% | +21.9% | — |
| Net income growth | +169.9% | +5.3% | — |
| EPS growth | +162.5% | -46.7% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.